AI-generated summary
This narrative review of the PubMed literature on photobiomodulation for intermediate age-related macular degeneration reports promising but inconsistent results, with some studies describing improved visual acuity, contrast sensitivity and reduced drusen volume. The authors state that long-term efficacy and optimal treatment parameters remain undetermined, and that evidence was limited, including only three randomized sham-controlled trials. They conclude that the effect on drusen resorption or progression to advanced disease remains uncertain.
- Who or what was studied
- Patients with intermediate age-related macular degeneration
- Limits stated in the abstract
- Variable irradiation techniques, wavelengths, exposure times and treatment sessions, imprecise AMD phenotype classification, limited sample sizes, unpublished results, and only three randomized sham-controlled trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Photobiomodulation, Photobiomodulation therapy, Adenosine triphosphate, Near-infrared, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.